Study of IKS04 for advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This study tests an investigational drug for people with certain advanced cancers that have not responded to other treatments. It may stop the cancer from growing by targeting a marker found on some tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer of the colon/rectum, bile ducts, stomach or esophagus, or pancreas.
- Your cancer has gotten worse despite prior treatment, and no other effective options are available.
- Your cancer cells have a marker called CA242, which will be checked by a lab.
- You have not had more than 5 prior cancer treatments.
- You are generally in good health (able to care for yourself) and have adequate blood cell counts and liver function.
- You do not have serious lung disease or a history of certain lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial tests a new drug (HS-10370) in combination with other cancer treatments for people with advanced solid tumors that have a specific genetic change (KRAS G12C). It's for patients who have tried standard options without success.
This trial is for people with a certain type of advanced colorectal cancer (MSS/pMMR) that has progressed after initial chemotherapy. It tests a new drug called AK112 combined with chemotherapy, compared to the standard treatment with bevacizumab plus chemotherapy. The goal is to see if the new combination works better as a second treatment option.
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.